From: Zoledronic acid ameliorates the effects of secondary osteoporosis in rheumatoid arthritis patients
Time | Combined | p* | ZOL | p* | MTX | p* | |
---|---|---|---|---|---|---|---|
Morning stiffness (min) | 0 M | 92.21 ± 47.69 | – | 81.29 ± 35.56 | – | 89.97 ± 36.42 | – |
6 M | 21.34 ± 16.10△ | < 0.001 | 71.27 ± 14.89△ | 0.371 | 44.15 ± 13.99 | 0.021 | |
12 M | 13.09 ± 14.43 | < 0.001 | 42.69 ± 13.56△ | 0.019 | 25.19 ± 14.21 | < 0.001 | |
A.1.1.1.1.1.1. VAS (mm) | 0 M | 64.36 ± 18.29 | – | 63.94 ± 17.83 | – | 65.28 ± 17.27 | – |
6 M | 37.90 ± 14.04△ | < 0.001 | 43.02 ± 16.20 | 0.040 | 40.08 ± 15.88 | 0.048 | |
12 M | 29.23 ± 16.13△ | < 0.001 | 37.02 ± 17.89△ | < 0.001 | 38.72 ± 17.25△ | < 0.001 | |
A.1.1.1.1.1.2. ESR(mm/h) | 0 M | 49.87 ± 27.68 | – | 50.43 ± 34.78 | – | 52.25 ± 37.96 | – |
6 M | 30.61 ± 21.56 | 0.022 | 40.25 ± 28.75△ | 0.467 | 37.21 ± 25.47△ | 0.038 | |
12 M | 23.58 ± 17.87 | 0.008 | 38.67 ± 22.87△ | 0.363 | 36.24 ± 21.46△ | 0.023 | |
A.1.1.1.1.1.3. CRP(mg/L) | 0 M | 25.14 ± 22.23 | – | 23.67 ± 27.35 | – | 26.21 ± 28.38 | – |
6 M | 13.57 ± 15.89 | 0.031 | 18.52 ± 29.51 | 0.077 | 15.39 ± 26.29 | 0.035 | |
12 M | 8.60 ± 12.27△ | 0.029 | 18.78 ± 23.38△ | 0.079 | 11.02 ± 20.12 | 0.019 | |
A.1.1.1.1.1.4. DAS28 | 0 M | 7.21 ± 1.27 | – | 7.17 ± 1.21 | – | 6.36 ± 1.45 | – |
6 M | 4.89 ± 1.26** | < 0.001 | 5.11 ± 1.33 | 0.036 | 4.27 ± 1.31 | 0.032 | |
12 M | 4.17 ± 1.21** | < 0.001 | 4.67 ± 1.28 | 0.019 | 4.12 ± 1.27 | 0.021 |